Hepatitis C Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | AbbVie, Gilead Sciences, Atea Pharma

The Key Hepatitis C Therapies in the market include - MAVYRET (Glecaprevir and Pibrentasvir), VOSEVI (sofosbuvir, velpatasvir, and voxilaprevir), EPCLUSA, Bemnifosbuvir + Ruzasvir, and others.
DelveInsight's "Hepatitis C Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Hepatitis C, historical and forecasted epidemiology as well as the Hepatitis C market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of Hepatitis C, offering comprehensive insights into the Hepatitis C revenue trends, prevalence, and treatment landscape. The report delves into key Hepatitis C statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Hepatitis C therapies. Additionally, we cover the landscape of Hepatitis C clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Hepatitis C treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Hepatitis C space.

To Know in detail about the Hepatitis C market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hepatitis C Market Forecast [https://www.delveinsight.com/sample-request/hepatitis-c-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Hepatitis C Market Report:

*
The Hepatitis C market size is anticipated to grow with a significant CAGR during the study period (2020-2034)

*
In July 2024, The World Health Organization (WHO) has prequalified the first self-test for hepatitis C, a disease caused by the hepatitis C virus (HCV) that impacts the liver. The virus can lead to both acute and chronic hepatitis, with symptoms ranging from mild illness to severe, lifelong conditions such as liver cirrhosis and cancer. Hepatitis C is bloodborne, with most infections resulting from exposure to blood through unsafe injection practices, unregulated healthcare procedures, blood transfusions, drug injection use, or blood exposure.

*
In June 2024, The FDA approved Cepheid's Xpert HCV test and GeneXpert Xpress System, representing a major breakthrough in Hepatitis C diagnostics by streamlining the process with a faster, test-and-treat method compared to conventional multi-step testing.

*
In 2023, the Hepatitis C Virus (HCV) market in the United States was valued at approximately USD 2,000 million.

*
In 2023, Genotype 1 represented around 70% of genotype-specific diagnosed Hepatitis C cases in the United States, emphasizing its high prevalence and the need for targeted treatment approaches.

*
The treatment of Hepatitis C has been revolutionized by direct-acting antivirals (DAAs) like HARVONI and Epclusa from Gilead Sciences, as well as VIEKIRA PAK from AbbVie, which provide high cure rates by targeting different stages of the virus. The introduction of MAVYRET by AbbVie in 2017 further broadened treatment options, strengthening global efforts to eliminate Hepatitis C.

*
Hepatitis C is a viral infection that primarily targets the liver, potentially causing acute and chronic liver disease if left untreated. Worldwide, nearly 50 million people live with chronic Hepatitis C, with around 1 million new cases each year. According to the WHO, approximately 242,000 deaths in 2022 were linked to Hepatitis C, mainly due to cirrhosis and hepatocellular carcinoma.

*
Key Hepatitis C Therapies: MAVYRET (Glecaprevir and Pibrentasvir), VOSEVI (sofosbuvir, velpatasvir, and voxilaprevir), EPCLUSA, Bemnifosbuvir + Ruzasvir, and others

*
Key Hepatitis C Companies: AbbVie, Gilead Sciences, Atea Pharmaceuticals, and others

*
Direct-acting antivirals (DAAs) like HARVONI and Epclusa from Gilead Sciences, and VIEKIRA PAK from AbbVie, have revolutionized Hepatitis C treatment by providing high cure rates and targeting different stages of the virus. AbbVie's MAVYRET, launched in 2017, broadened treatment options, significantly contributing to the global initiative to eradicate Hepatitis C.

*
The Hepatitis C market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hepatitis C pipeline products will significantly revolutionize the Hepatitis C market dynamics.

*
In 2023, approximately 2.1 million diagnosed cases of Hepatitis C were recorded in the United States.

*
In the same year, males accounted for roughly 60% of the cases in the EU4 countries and the UK.

*
In Japan, individuals aged 46-55 represented approximately 70% of Hepatitis C cases in 2023.

Hepatitis C Overview

Hepatitis C is a viral infection caused by the Hepatitis C virus (HCV) that primarily affects the liver. It can lead to both acute and chronic liver disease, including cirrhosis, liver failure, and liver cancer if left untreated. The virus spreads through blood-to-blood contact, often via shared needles, unsterile medical equipment, or transfusions of unscreened blood.

Get a Free sample for the Hepatitis C Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/hepatitis-c-market [https://www.delveinsight.com/report-store/hepatitis-c-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Hepatitis C Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Hepatitis C Epidemiology Segmentation:

The Hepatitis C market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

*
Total Prevalence of Hepatitis C

*
Prevalent Cases of Hepatitis C by severity

*
Gender-specific Prevalence of Hepatitis C

*
Diagnosed Cases of Episodic and Chronic Hepatitis C

Download the report to understand which factors are driving Hepatitis C epidemiology trends @ Hepatitis C Epidemiology Forecast [https://www.delveinsight.com/sample-request/hepatitis-c-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Hepatitis C Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hepatitis C market or expected to get launched during the study period. The analysis covers Hepatitis C market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Hepatitis C Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Hepatitis C Therapies and Key Companies

*
MAVYRET (Glecaprevir and Pibrentasvir): AbbVie

*
VOSEVI (sofosbuvir, velpatasvir, and voxilaprevir): Gilead Sciences

*
EPCLUSA: Gilead Sciences

*
Bemnifosbuvir + Ruzasvir: Atea Pharmaceuticals

Discover more about therapies set to grab major Hepatitis C market share @ Hepatitis C Treatment Landscape [https://www.delveinsight.com/sample-request/hepatitis-c-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Hepatitis C Market Drivers

*
Advancements in Antiviral Treatments

*
Increased Screening and Early Detection

*
Government Initiatives

*
Improved Patient Access

*
Global Collaboration

*
Rising Awareness

Hepatitis C Market Barriers

*
High Treatment Costs

*
Geographical Disparities

*
Stigma and Lack of Awareness

*
Complicated Diagnosis in Early Stages

*
Co-infection with Other Diseases

*
Limited Healthcare Infrastructure

Scope of the Hepatitis C Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Hepatitis C Therapies: MAVYRET (Glecaprevir and Pibrentasvir), VOSEVI (sofosbuvir, velpatasvir, and voxilaprevir), EPCLUSA, Bemnifosbuvir + Ruzasvir, and others

*
Key Hepatitis C Companies: AbbVie, Gilead Sciences, Atea Pharmaceuticals, and others

*
Hepatitis C Therapeutic Assessment: Hepatitis C current marketed and Hepatitis C emerging therapies

*
Hepatitis C Market Dynamics: Hepatitis C market drivers and Hepatitis C market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Hepatitis C Unmet Needs, KOL's views, Analyst's views, Hepatitis C Market Access and Reimbursement

To know more about Hepatitis C companies working in the treatment market, visit @ Hepatitis C Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/hepatitis-c-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Hepatitis C Market Report Introduction

2. Executive Summary for Hepatitis C

3. SWOT analysis of Hepatitis C

4. Hepatitis C Patient Share (%) Overview at a Glance

5. Hepatitis C Market Overview at a Glance

6. Hepatitis C Disease Background and Overview

7. Hepatitis C Epidemiology and Patient Population

8. Country-Specific Patient Population of Hepatitis C

9. Hepatitis C Current Treatment and Medical Practices

10. Hepatitis C Unmet Needs

11. Hepatitis C Emerging Therapies

12. Hepatitis C Market Outlook

13. Country-Wise Hepatitis C Market Analysis (2020-2034)

14. Hepatitis C Market Access and Reimbursement of Therapies

15. Hepatitis C Market Drivers

16. Hepatitis C Market Barriers

17. Hepatitis C Appendix

18. Hepatitis C Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=hepatitis-c-market-growth-to-accelerate-in-forecast-period-20242034-delveinsight-analyzes-abbvie-gilead-sciences-atea-pharma]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.